Luye Pharma Group Ltd.
LYPHF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $6,061,441 | $6,143,078 | $5,981,656 | $5,200,226 |
| % Growth | -1.3% | 2.7% | 15% | – |
| Cost of Goods Sold | $2,017,214 | $1,938,903 | $1,841,140 | $1,803,486 |
| Gross Profit | $4,044,227 | $4,204,175 | $4,140,516 | $3,396,740 |
| % Margin | 66.7% | 68.4% | 69.2% | 65.3% |
| R&D Expenses | $498,587 | $586,157 | $857,337 | $683,156 |
| G&A Expenses | $581,962 | $643,967 | $582,870 | $570,844 |
| SG&A Expenses | $2,398,390 | $2,700,134 | $2,402,561 | $2,275,624 |
| Sales & Mktg Exp. | $1,816,428 | $2,056,167 | $1,819,691 | $1,704,780 |
| Other Operating Expenses | -$143,805 | -$110,841 | -$73,260 | $155,154 |
| Operating Expenses | $2,753,172 | $3,175,450 | $3,186,638 | $3,113,934 |
| Operating Income | $1,291,055 | $1,028,725 | $1,214,982 | $386,987 |
| % Margin | 21.3% | 16.7% | 20.3% | 7.4% |
| Other Income/Exp. Net | -$451,836 | -$328,625 | -$210,856 | -$512,517 |
| Pre-Tax Income | $839,219 | $700,100 | $669,762 | -$74,557 |
| Tax Expense | $194,211 | $161,023 | $86,466 | $70,226 |
| Net Income | $471,886 | $532,605 | $604,807 | -$144,783 |
| % Margin | 7.8% | 8.7% | 10.1% | -2.8% |
| EPS | 0.018 | 0.14 | 0.17 | -0.042 |
| % Growth | -87.5% | -17.6% | 504.8% | – |
| EPS Diluted | 0.018 | 0.14 | 0.17 | -0.042 |
| Weighted Avg Shares Out | 3,761,671 | 3,728,369 | 3,480,853 | 3,445,431 |
| Weighted Avg Shares Out Dil | 3,761,671 | 3,728,363 | 3,480,853 | 3,445,431 |
| Supplemental Information | – | – | – | – |
| Interest Income | $84,432 | $117,137 | $88,673 | $101,996 |
| Interest Expense | $561,785 | $675,454 | $471,755 | $399,458 |
| Depreciation & Amortization | $790,672 | $701,851 | $671,313 | $581,982 |
| EBITDA | $2,191,676 | $2,077,405 | $1,812,830 | $906,883 |
| % Margin | 36.2% | 33.8% | 30.3% | 17.4% |